Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (758)	3/4/2000 1:51:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

Ashley: Hey, you're talking to the second floor guy. Fortunately, I've (1) kept little chunks, (2) traded myself into a competitive performance with minimal bets, and (3) found valuation plays like KDUS and Shahram's NBSC. Sure wish, however, that I'd have gone with the feel and let bets ride. Of late, every dotcom gunslinger in the world who has crossed over to biotech has beaten me. <g> Don't know about the CBMI example, but value was created NPSP (biowa! biowa!) and MLNM/LKST. These events helped to solidify the rally. In fact, I feel that the MLNM/LKST merger was the stealth trigger. Liquidity flow to the sector has gone beyond what could have been conceived when those mergers were effected, and, yes, the op to create value is even greater now. Merge, merge, merge, merge. Now is the time to even the playing field. Pipelines and platforms were worth squat eighteen months ago. Let's see what Haseltine can do. He's out on a limb, but, geeeeze, he looks comfortable out there. <vbg> Rick